OptiNose AS

99 articles with OptiNose AS

• Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 25, 2021

  8/25/2021

  OptiNose, Inc., a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that the company has granted non-qualified stock option awards to purchase an aggregate of 60,000 shares of its common stock to seven new employees as an inducement material for accepting employment with OptiNose.

• Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

  8/11/2021

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2021, and provided operational updates.

• Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million

  7/28/2021

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced preliminary XHANCE® net product revenue of $18.4 million for the three months ended June 30, 2021.

• Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry

  6/24/2021

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced Dr. Per Djupesland received the European Inventor Award 2021 in the Industry category from the European Patent Office for his invention of the technology that serves as a basis for the Optinose Exhalation Delivery System.

• Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care

  6/2/2021

  Evidenced-based expert algorithm separates EDS-FLU, marketed as XHANCE®, from standard intranasal steroid sprays, recommending it for patients with nasal polyps whose symptoms persist after using standard intranasal steroid sprays

• Optinose to Present at the Jefferies Virtual Healthcare Conference

  6/1/2021

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET.

• Optinose Reports First Quarter 2021 Financial Results and Operational Updates

  5/5/2021

  Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time

• Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation

  4/28/2021

  Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021

• New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day

  4/27/2021

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced results of a new nationwide survey on chronic nasal congestion, its impact on daily activities, and awareness of nasal polyps as a possible cause.

• Optinose to Present at the Needham Virtual Healthcare Conference

  4/12/2021

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Needham Virtual Healthcare Conference on April 15, 2021, at 11:45 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

• Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

  3/3/2021

  Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects XHANCE net revenue for 2021 to be at least $80 million

• Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results

  2/17/2021

  Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time Company to Present at the Cowen 41 st Annual Health Care Conference on March 4, 2021

• Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/25/2021

  OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 15,000 shares of its common stock to one new employee as an inducement material for accepting employment with OptiNose

• Optinose Announced Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  12/21/2020

  Opti N ose , Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of 35,000 shares of its common stock to two new employees as an inducement material to them accepting employment with OptiNose. The stock option awards were approved by the Compensation Committee of the

• Optinose Announces Changes to Board of Directors - Dec 01, 2020

  12/1/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced its Board of Directors has named Tomas J. Heyman as a new director.

• Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

  11/5/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the three and nine months ended September 30, 2020, and provided operational updates.

• Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million

  10/22/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced preliminary XHANCE® net product revenues of $15.4 million for the three months ended September 30, 2020.

• Optinose Announces Pricing of Public Offering of Common Stock - Aug 14, 2020

  8/14/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the pricing of its previously announced public offering of 6,000,000 shares of common stock at a price to the public of $5.85 per share. All of the shares of common stock will be offered by Optinose.

• Optinose Announces Proposed Public Offering of Common Stock - Aug 13, 2020

  8/13/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the commencement of a proposed underwritten public offering of shares of its common stock.

• Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights 

  8/4/2020

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2020, and provided operational updates.